SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Brooks Laboratories - Quaterly Results

10 Aug 2022 Evaluate
A slight decline in the revenue of Rs. 149.43 millions was seen for the June 2022 quarter as against Rs. 155.81 millions during year-ago period.The Net Loss for the quarter ended June 2022 is Rs. -45.70 millions as compared to Net Profit of Rs. 14.24 millions of corresponding quarter ended June 2021Operating profit Margin for the quarter ended June 2022 slipped to -39.90% as compared to 19.62% of corresponding quarter ended June 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 149.43 155.81 -4.09 149.43 155.81 -4.09 769.67 772.47 -0.36
Other Income 0.46 9.23 -95.02 0.46 9.23 -95.02 9.48 9.88 -4.05
PBIDT -39.90 19.62 -303.36 -39.90 19.62 -303.36 28.23 17.53 61.04
Interest 1.57 1.81 -13.26 1.57 1.81 -13.26 6.70 30.94 -78.35
PBDT -41.47 17.81 -332.85 -41.47 17.81 -332.85 21.53 -13.41 -260.55
Depreciation 4.23 3.57 18.49 4.23 3.57 18.49 14.86 70.93 -79.05
PBT -45.70 14.24 -420.93 -45.70 14.24 -420.93 6.67 -84.34 -107.91
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 71.52 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -45.70 14.24 -420.93 -45.70 14.24 -420.93 6.67 -155.86 -104.28
Equity 247.03 247.03 0.00 247.03 247.03 0.00 247.03 247.03 0.00
PBIDTM(%) -26.70 12.59 -312.05 -26.70 12.59 -312.05 3.67 2.27 61.63

Brooks Laboratories Share Price

62.05 -2.61 (-4.04%)
22-Apr-2026 10:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1656.80
Dr. Reddys Lab 1214.95
Cipla 1227.00
Zydus Lifesciences 928.25
Lupin 2308.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×